Sanofi Ventures
Sanofi's strategic venture fund, which invests in early biotech and digital health companies before they are ready to partner with or be bought by Sanofi. Cancer-related holdings include the radiopharmaceutical company AdvanCell and the immune checkpoint company Abcuro.
Overview
Sanofi Ventures describes itself as 'a strategic venture fund' and 'an entry point to the innovation ecosystem for Sanofi, strategically investing in early-stage transformational science and technology, when companies are too early to partner with or acquire'. It invests 'across all stages of the private company lifecycle, from Seed to Series B and beyond', leading financings and taking board seats in biotech and digital health companies. Its portfolio page includes AdvanCell (a lead-212 radiotherapeutics company advancing a PSMA-targeting radioligand for prostate cancer, which closed a $315 million Series D in July 2026 and has a collaboration with Lilly), Abcuro (anti-KLRG1 antibodies for autoimmune and cancer indications, including ABC015 to reactivate cytotoxic T and NK cells in the tumour microenvironment) and bluebird bio (gene therapy, with an oncology CAR-T collaboration).
Portfolio in OnCo (2)
Filter the startups table| Company | Stage | Type | Cancers | Latest round |
|---|---|---|---|---|
| Nucleai Tel Aviv, IL | Startup | ai software | none on record | |
| Trial Library San Francisco, CA, US | Startup | ai software | Series A 2025, $10M |
Notes
top- Founding year and office address not stated on fetched pages; Cambridge, MA follows the task hint.